Exposure of nasal mucosa to various allergic and/or non-allergic stimuli might result in rhinitis. Allergic rhinitis affects 10-25% of population making it the most prevalent allergic disorder. Seasonal and perennial allergic rhinitis affect up to 30% and 10% of pediatric population, respectively. Prevalence of allergic rhinitis varies between studies: in Poland, Breborowicz et al. reported allergic rhinitis in 16.7% of children aged 6-7, whereas Emeryk et al. observed perennial allergic rhinitis in 3.6% and seasonal allergic rhinitis in 6.2% of 8-15 year olds.
Allergic rhinitis similarly to other diseases results in direct, indirect and hidden costs. In the USA (2002) direct costs were estimated at $4.195 billions and indirect at $665 millions (total of $4.863 billions).
Allergic rhinitis co-exists with multiple respiratory conditions, significantly increasing treatment costs incurred by patients’ and places additional burden on public finances. It also has a detrimental effect on patients’ and their families’ quality of life.
Allergic rhinitis - although non-life threatening - significantly worsens quality of daily life and as such should be perceived as a serious medical condition not only by patients but also by medical professionals who are in position to diagnose it and implement appropriate therapeutic interventions.